BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34398984)

  • 21. Analysis of METTL3 and METTL14 in hepatocellular carcinoma.
    Liu X; Qin J; Gao T; Li C; Chen X; Zeng K; Xu M; He B; Pan B; Xu X; Pan Y; Sun H; Xu T; Wang S
    Aging (Albany NY); 2020 Nov; 12(21):21638-21659. PubMed ID: 33159022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma.
    Chen Y; Ling Z; Cai X; Xu Y; Lv Z; Man D; Ge J; Yu C; Zhang D; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
    Cancer Res; 2022 Feb; 82(4):599-614. PubMed ID: 34916222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA.
    Fu W; Liu L; Tong S
    Thorac Cancer; 2024 Jun; 15(17):1357-1368. PubMed ID: 38709912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. METTL3 facilitates tumor progression via an m
    Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
    Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
    Meng QZ; Cong CH; Li XJ; Zhu F; Zhao X; Chen FW
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4328-4336. PubMed ID: 32373970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
    Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S
    Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. METTL3 promotes m6A hypermethylation of RBM14 via YTHDF1 leading to the progression of hepatocellular carcinoma.
    Hu J; Yang L; Peng X; Mao M; Liu X; Song J; Li H; Chen F
    Hum Cell; 2022 Nov; 35(6):1838-1855. PubMed ID: 36087219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.
    Miao W; Chen J; Jia L; Ma J; Song D
    Biochem Biophys Res Commun; 2019 Aug; 516(3):719-725. PubMed ID: 31253399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. METTL3 and STAT3 form a positive feedback loop to promote cell metastasis in hepatocellular carcinoma.
    Liu B; Cao J; Wu B; Hao K; Wang X; Chen X; Shen Z
    Cell Commun Signal; 2023 May; 21(1):121. PubMed ID: 37231451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2.
    Zhou L; Yang C; Zhang N; Zhang X; Zhao T; Yu J
    Biomed Pharmacother; 2020 May; 125():109964. PubMed ID: 32044716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m
    Liu L; Wu Y; Li Q; Liang J; He Q; Zhao L; Chen J; Cheng M; Huang Z; Ren H; Chen J; Peng L; Gao F; Chen D; Wang A
    Mol Ther; 2020 Oct; 28(10):2177-2190. PubMed ID: 32621798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methyltransferase-like 3 (METTL3) mediated N6-methyladenosine (m6A) modifications facilitate mir-25-3p maturation to promote gastrointestinal stromal tumors (GISTs) progression.
    Qian K; Xu W; Xia X; Ding J
    Genes Genomics; 2022 Dec; 44(12):1519-1530. PubMed ID: 36040683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. m
    Shen C; Xuan B; Yan T; Ma Y; Xu P; Tian X; Zhang X; Cao Y; Ma D; Zhu X; Zhang Y; Fang JY; Chen H; Hong J
    Mol Cancer; 2020 Apr; 19(1):72. PubMed ID: 32245489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylation recognition protein YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) regulates the proliferation, migration and invasion of osteosarcoma by regulating m6A level of CCR4-NOT transcription complex subunit 7 (CNOT7).
    Wei K; Gao Y; Wang B; Qu YX
    Bioengineered; 2022 Mar; 13(3):5236-5250. PubMed ID: 35156522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways.
    Chen SL; Liu LL; Wang CH; Lu SX; Yang X; He YF; Zhang CZ; Yun JP
    Mol Oncol; 2020 Feb; 14(2):373-386. PubMed ID: 31670863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation.
    Lin C; Li T; Wang Y; Lai S; Huang Y; Guo Z; Zhang X; Weng S
    Cell Death Dis; 2023 Mar; 14(3):221. PubMed ID: 36977668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNA m
    Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
    EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma.
    Qi LW; Jia JH; Jiang CH; Hu JM
    Front Genet; 2020; 11():614566. PubMed ID: 33519919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. METTL3 promotes the growth and metastasis of pancreatic cancer by regulating the m6A modification and stability of E2F5.
    Tang Y; Gao G; Xia WW; Wang JB
    Cell Signal; 2022 Nov; 99():110440. PubMed ID: 35985439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma.
    Liu L; He J; Sun G; Huang N; Bian Z; Xu C; Zhang Y; Cui Z; Xu W; Sun F; Zhuang C; Man Q; Gu S
    Clin Transl Med; 2022 May; 12(5):e778. PubMed ID: 35522946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.